Binetrakin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Binetrakin
Accession Number
DB12182
Type
Biotech
Groups
Investigational
Description

Binetrakin has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, Non-Hodgkin's Lymphoma (NHL), Myelodysplastic Syndrome (MDS), and Leukemia, Acute Myelogenous (AML), among others.

Protein structure
No structure small
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • IL-4
  • Interleukin 4 (human)
  • Interleukin 4 human
  • Interleukin-4
  • Interleukin-4 (human; nonglycosylated)
External IDs
Not Available
Product Ingredients
Not Available
Approved Prescription Products
Not Available
Approved Generic Prescription Products
Not Available
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Not Available
Brand mixtures
Not Available
Categories
UNII
751635Z921
CAS number
207137-56-2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Il 4.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Il 4.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Il 4.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Il 4.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Il 4.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Il 4.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Il 4.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Il 4.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Il 4.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Il 4.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Il 4.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Il 4.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Not Available
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
1, 2CompletedTreatmentLeukemia, Acute Lymphocytic (ALL) / Leukemia, Acute Myelogenous (AML) / Leukemia, Chronic Myelogenous (CML) / Myelodysplastic Syndromes (MDS) / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentEwing's Sarcoma (ES) / Rhabdomyosarcomas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Drug created on October 20, 2016 15:33 / Updated on June 28, 2017 10:03